Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer.

29 Yang et al found marginally nonsignificant differences in OS (median: C-SCLC, 10.00 vs pure SCLC, 9.00 months; P = 0.17) based on the SEER database. 30 Although the current C-SCLC case had progressed to stage IV at the initial diagnosis, her survival time far exceeded the median overall survival times of previously reported C-SCLC patients with active and reasonable treatment strategies.

also in 145 other papers